Viking Therapeutics (VKTX) Competitors $51.53 +0.02 (+0.04%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends VKTX vs. ICPT, PRTA, PBYI, MRNS, TEVA, BGNE, VTRS, SMMT, MRNA, and GMABShould you be buying Viking Therapeutics stock or one of its competitors? The main competitors of Viking Therapeutics include Intercept Pharmaceuticals (ICPT), Prothena (PRTA), Puma Biotechnology (PBYI), Marinus Pharmaceuticals (MRNS), Teva Pharmaceutical Industries (TEVA), BeiGene (BGNE), Viatris (VTRS), Summit Therapeutics (SMMT), Moderna (MRNA), and Genmab A/S (GMAB). These companies are all part of the "medical" sector. Viking Therapeutics vs. Intercept Pharmaceuticals Prothena Puma Biotechnology Marinus Pharmaceuticals Teva Pharmaceutical Industries BeiGene Viatris Summit Therapeutics Moderna Genmab A/S Viking Therapeutics (NASDAQ:VKTX) and Intercept Pharmaceuticals (NASDAQ:ICPT) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, community ranking, valuation, dividends and media sentiment. Does the MarketBeat Community favor VKTX or ICPT? Intercept Pharmaceuticals received 452 more outperform votes than Viking Therapeutics when rated by MarketBeat users. However, 79.74% of users gave Viking Therapeutics an outperform vote while only 71.26% of users gave Intercept Pharmaceuticals an outperform vote. CompanyUnderperformOutperformViking TherapeuticsOutperform Votes61479.74% Underperform Votes15620.26% Intercept PharmaceuticalsOutperform Votes106671.26% Underperform Votes43028.74% Do analysts rate VKTX or ICPT? Viking Therapeutics presently has a consensus price target of $109.80, indicating a potential upside of 113.08%. Given Viking Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Viking Therapeutics is more favorable than Intercept Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Viking Therapeutics 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.09Intercept Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility & risk, VKTX or ICPT? Viking Therapeutics has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.Comparatively, Intercept Pharmaceuticals has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500. Is VKTX or ICPT more profitable? Viking Therapeutics has a net margin of 0.00% compared to Intercept Pharmaceuticals' net margin of -19.39%. Viking Therapeutics' return on equity of -12.73% beat Intercept Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Viking TherapeuticsN/A -12.73% -12.31% Intercept Pharmaceuticals -19.39%-77.48%-11.99% Do institutionals and insiders hold more shares of VKTX or ICPT? 76.0% of Viking Therapeutics shares are owned by institutional investors. Comparatively, 83.8% of Intercept Pharmaceuticals shares are owned by institutional investors. 4.7% of Viking Therapeutics shares are owned by insiders. Comparatively, 6.2% of Intercept Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the media refer more to VKTX or ICPT? In the previous week, Viking Therapeutics had 25 more articles in the media than Intercept Pharmaceuticals. MarketBeat recorded 25 mentions for Viking Therapeutics and 0 mentions for Intercept Pharmaceuticals. Viking Therapeutics' average media sentiment score of 0.48 beat Intercept Pharmaceuticals' score of 0.30 indicating that Viking Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Viking Therapeutics Neutral Intercept Pharmaceuticals Neutral Which has stronger valuation & earnings, VKTX or ICPT? Intercept Pharmaceuticals has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Intercept Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioViking TherapeuticsN/AN/A-$85.89M-$0.93-55.41Intercept Pharmaceuticals$285.71M2.78$221.82M-$1.48-12.84 SummaryViking Therapeutics beats Intercept Pharmaceuticals on 11 of the 18 factors compared between the two stocks. Ad DTIDownload Our Tesla Ebook For FreeLike many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.To claim your copy free of charge simply follow this link. Get Viking Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VKTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VKTX vs. The Competition Export to ExcelMetricViking TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.74B$6.45B$5.03B$8.81BDividend YieldN/A8.11%5.16%4.06%P/E Ratio-55.4110.78135.4117.82Price / SalesN/A243.751,160.9774.56Price / CashN/A22.1633.5332.53Price / Book14.815.474.674.68Net Income-$85.89M$153.61M$119.07M$226.08M7 Day Performance-3.81%-2.00%-1.83%-1.04%1 Month Performance-19.91%-7.46%-3.60%1.04%1 Year Performance354.01%31.82%31.66%26.28% Viking Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VKTXViking Therapeutics4.7706 of 5 stars$51.53+0.0%$109.80+113.1%+337.8%$5.74BN/A-55.4120Analyst ForecastGap UpICPTIntercept PharmaceuticalsN/A$19.00flatN/AN/A$794.77M$285.71M-12.84341PRTAProthena1.6434 of 5 stars$14.40+2.5%$61.86+329.6%-57.8%$756.02M$133.35M-5.81173Analyst DowngradeAnalyst RevisionPBYIPuma Biotechnology4.4109 of 5 stars$2.84+3.6%$7.00+146.5%-27.0%$139.42M$235.60M5.92185Analyst ForecastPositive NewsMRNSMarinus Pharmaceuticals4.5957 of 5 stars$0.31flat$4.79+1,448.8%-95.0%$17.05M$30.99M-0.13110Analyst ForecastAnalyst RevisionTEVATeva Pharmaceutical Industries2.7309 of 5 stars$17.03+1.2%$19.67+15.5%+80.0%$19.29B$15.85B-20.0337,851BGNEBeiGene3.174 of 5 stars$194.26+3.5%$247.07+27.2%+3.4%$18.92B$2.46B-23.5810,600Gap UpVTRSViatris1.3563 of 5 stars$13.13+0.6%$13.33+1.5%+38.6%$15.67B$15.05B-17.7438,000SMMTSummit Therapeutics1.863 of 5 stars$18.62-6.9%$34.75+86.6%+835.7%$14.75B$700,000.00-66.50105Analyst ForecastMRNAModerna4.6267 of 5 stars$36.94-0.9%$84.00+127.4%-53.2%$14.22B$6.85B-6.355,600Analyst UpgradeAnalyst RevisionGMABGenmab A/S4.3059 of 5 stars$20.45-0.2%$45.20+121.0%-37.0%$13.53B$19.84B19.852,204 Related Companies and Tools Related Companies Intercept Pharmaceuticals Competitors Prothena Competitors Puma Biotechnology Competitors Marinus Pharmaceuticals Competitors Teva Pharmaceutical Industries Competitors BeiGene Competitors Viatris Competitors Summit Therapeutics Competitors Moderna Competitors Genmab A/S Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VKTX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viking Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viking Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VKTX Stock Alerts